Mednet Logo
HomeRheumatology
Rheumatology

Rheumatology

Clinical discussions on autoimmune diseases, biologic therapies, vasculitis, and musculoskeletal conditions.

Recent Discussions

Would you start hydroxychloroquine (or another DMARD) in a mid-20s female patient with positive ANA, SSA, SSB, and dsDNA, whose only clinical manifestation is intermittent parotid gland swelling?

1
6 Answers

Mednet Member
Mednet Member
Rheumatology · U.S. Department of Veterans Affairs

Hmm... I think the better question to ask is, do you code as Sjogren's lupus overlap to get way more medication options? Certainly, HCQ is a reasonable DMARD and a place to start for both diseases. I would code as lupus and Sjogren's to have more options for the future. Hope someone can weigh in on ...

How do you approach adding colchicine to a patient who is on a stable statin regimen?

4
2 Answers

Mednet Member
Mednet Member
Rheumatology · Mobile Medical Care Inc

This is a good question and a tough situation, since the drug-drug interaction here can be as subtle as myalgias but as severe as rhabdomyolysis (rare but happens). If you can avoid long-term colchicine in this situation, it is always best. These situations (hypercholesterolemia and crystal arthropa...

How do you interpret treatment response in the DISCOVER-2 Trial when patients were allowed to remain on up to 10mg of prednisone equivalent for disease control while on guselkumab?

3 Answers

Mednet Member
Mednet Member
Rheumatology · Leiden University Medical Center

The dependence on the use of systemic glucocorticoids may indeed be a good reason to change treatment. Especially in patients with psoriatic arthritis. So, if patients are unable to stop systemic glucocorticoids and there are still treatment options for the patient, this could be tried. It is diffic...

In patients with inflammatory arthritis (RA, psoriatic arthritis) and a history of MGUS are there any concerns regarding use of biologics?

1 Answers

Mednet Member
Mednet Member
Rheumatology · Rheumatology Associates of Long Island

There is no absolute contraindication to any particular biologic used to manage active RA in a patient with MGUS. The literature does point out a small potential risk associated with tocilizumab in terms of development of myeloma influenced by the IL-6 pathway (and I would tend to extend that potent...

Do you routinely transition to PO antibiotics for patients with native joint septic arthritis whom have undergone washout and the organism is not S. aureus?

1
1 Answers

Mednet Member
Mednet Member
Infectious Disease · University of Michigan

Yes. Even if the organism is Staph aureus, I would feel comfortable with an appropriate, highly bioavailable oral antibiotics after appropriate source control (linezolid in the case of Staph aureus).

Would you offer re-irradiation LDRT for someone with osteoarthritis or tendinitis if symptoms recur?

3
2 Answers

Mednet Member
Mednet Member
Radiation Oncology · Vanderbilt University Medical Center

I have not personally offered a patient a third round of LDRT and do not know of any data that shows efficacy. However, I might offer a third round if a particular patient got adequate results with the first two and there was some separation in time (perhaps >1 year) since the last round.

In a patient with known APS (triple positive) and interstitial lung disease (NSIP), how do you distinguish APS associated lung involvement from connective tissue disease related ILD?

1 Answers

Mednet Member
Mednet Member
Rheumatology · University of Washington

Patients with APS typically have vascular and thrombotic pulmonary disease, and very rarely has interstitial disease been ascribed to APS. The most common pulmonary manifestation of APS is pulmonary embolism, occurring in 14-16% of patients, followed by pulmonary hypertension often caused by chronic...

How often are you performing CT screening in CVID patients to screen for ILD?

3
1 Answers

Mednet Member
Mednet Member
Allergy & Immunology · Medical University of South Carolina

CT once every 1-2 years, depending on symptoms and PFTs. PFTs, including DLCO, are annually performed.

With the increasing availability of biosimilars and their adoption onto payer formularies, how do you approach selection among available biosimilars in clinical practice?

2 Answers

Mednet Member
Mednet Member
Rheumatology · Texas Christian University

Insurance payers consider FDA‑approved biosimilars to be clinically equivalent. In my experience, selection is ultimately driven by the insurance payer formulary - what you can get for the patient on the time. This can be fleeting and quickly changing at times. Cases can be made for patient experien...

Do you routinely supplement folic acid in patients with rheumatoid arthritis who are taking sulfasalazine?

2 Answers

Mednet Member
Mednet Member
Rheumatology · Duke University Medical Center

No, I do not routinely use folic acid supplementation in patients with RA on sulfasalazine. It is recommended to supplement FA for those taking sulfasalazine in pregnancy.CC @Dr. First Last if any additional comments on this!